Na Seunghee, Jeong Hyeonseok, Park Jong-Sik, Chung Yong-An, Song In-Uk
Department of Neurology, Incheon St. Mary's Hospital, The Catholic University of Korea, Seoul 21431, Korea.
Department of Radiology, Incheon St. Mary's Hospital, The Catholic University of Korea, Seoul 21431, Korea.
Metabolites. 2020 Sep 23;10(10):380. doi: 10.3390/metabo10100380.
The neuropathology of Parkinson's disease dementia (PDD) is heterogenous, and the impacts of each pathophysiology and their synergistic effects are not fully understood. The aim of this study was to evaluate the frequency and impacts of co-existence with Alzheimer's disease in patients with PDD by using 18F-florbetaben PET imaging. A total of 23 patients with PDD participated in the study. All participants underwent 18F-florbetaben PET and completed a standardized neuropsychological battery and assessment of motor symptoms. The results of cognitive tests, neuropsychiatric symptoms, and motor symptoms were analyzed between the positive and negative 18F-florbetaben PET groups. Four patients (17.4%) showed significant amyloid burden. Patients with amyloid-beta showed poorer performance in executive function and more severe neuropsychiatric symptoms than those without amyloid-beta. Motor symptoms assessed by UPDRS part III and the modified H&Y Scale were not different between the two groups. The amyloid PET scan of a patient with PDD can effectively reflect a co-existing Alzheimer's disease pathology. Amyloid PET scans might be able to help physicians of PDD patients showing rapid progression or severe cognitive/behavioral features.
帕金森病痴呆（PDD）的神经病理学具有异质性，每种病理生理学的影响及其协同作用尚未完全明确。本研究旨在通过使用18F-氟代贝他苯PET成像评估PDD患者中阿尔茨海默病共存的频率及其影响。共有23例PDD患者参与了本研究。所有参与者均接受了18F-氟代贝他苯PET检查，并完成了标准化神经心理成套测验以及运动症状评估。对18F-氟代贝他苯PET阳性组和阴性组之间的认知测试、神经精神症状和运动症状结果进行了分析。4例患者（17.4%）显示出明显的淀粉样蛋白负荷。与无淀粉样蛋白的患者相比，有β-淀粉样蛋白的患者在执行功能方面表现较差，神经精神症状更严重。两组之间由统一帕金森病评定量表第三部分（UPDRS part III）和改良的 Hoehn-Yahr（H&Y）量表评估的运动症状并无差异。PDD患者的淀粉样蛋白PET扫描能够有效反映共存的阿尔茨海默病病理情况。淀粉样蛋白PET扫描或许能够帮助诊治具有快速进展或严重认知/行为特征表现的PDD患者。
